Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -402.92% is 96% below its 4-year average of -205.86%, around the middle of its 4-year range (-676.56%–-73.84%).
As of the fiscal period ended Tuesday, June 30, 2026. 33.52% below its 12-month average of -301.77%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -402.92%.
RETURN ON EQUITY (ROE)
-402.92%
RETURN ON EQUITY (ROE) AVG TTM
-301.77%
RETURN ON EQUITY (ROE) AVG 3Y
-238.87%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-33.52%
CURRENT VS 3Y AVG
-68.68%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.25%
median of 444 covered companies
CURRENT VS SECTOR MEDIAN
-953.39%
vs the sector median at left
bioAffinity Technologies, Inc.
Market Cap
$2.59M
Return on Equity (ROE)
-402.92%
TTM Avg
-301.77%
3Y Avg
-238.87%
5Y Avg
N/A
Market Cap
$2.64M
Return on Equity (ROE)
-657.69%
TTM Avg
-358.53%
3Y Avg
-220.37%
5Y Avg
-149.08%
Market Cap
$2.47M
Return on Equity (ROE)
-391.26%
TTM Avg
-355.49%
3Y Avg
-474.62%
5Y Avg
-295.97%
Market Cap
$2.38M
Return on Equity (ROE)
-83.26%
TTM Avg
-46.97%
3Y Avg
-39.40%
5Y Avg
-27.49%
Market Cap
$2.37M
Return on Equity (ROE)
-69.79%
TTM Avg
-83.20%
3Y Avg
-70.37%
5Y Avg
-0.36%
Market Cap
$2.36M
Return on Equity (ROE)
-1160.10%
TTM Avg
-528.10%
3Y Avg
-389.86%
5Y Avg
-336.02%
Market Cap
$3.09M
Return on Equity (ROE)
-365.43%
TTM Avg
-2048.73%
3Y Avg
-1082.52%
5Y Avg
-614.77%
Market Cap
$2.05M
Return on Equity (ROE)
-554.01%
TTM Avg
-109.66%
3Y Avg
1542.76%
5Y Avg
920.25%
Market Cap
$3.13M
Return on Equity (ROE)
N/A
TTM Avg
-236.13%
3Y Avg
-104.67%
5Y Avg
-48.54%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | $2.59M | -402.92% | -301.77% | -238.87% | N/A |
| iSpecimen Inc. (ISPC)vs › | $2.64M | -657.69% | -358.53% | -220.37% | -149.08% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.47M | -391.26% | -355.49% | -474.62% | -295.97% |
| iTonic Holdings Ltd. (ITOC)vs › | $2.38M | -83.26% | -46.97% | -39.40% | -27.49% |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.37M | -69.79% | -83.20% | -70.37% | -0.36% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.36M | -1160.10% | -528.10% | -389.86% | -336.02% |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.09M | -365.43% | -2048.73% | -1082.52% | -614.77% |
| Jaguar Health, Inc. (JAGX)vs › | $2.05M | -554.01% | -109.66% | 1542.76% | 920.25% |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.13M | N/A | -236.13% | -104.67% | -48.54% |
| Autonomix Medical, Inc. (AMIX)vs › | $1.92M | -509.36% | -212.22% | -233.92% | -323.18% |
ROE
-402.9%
ROA
-199.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -402.92% |
| 2026-03-31 | -433.71% |
| 2025-12-31 | -204.87% |
| 2025-09-30 | -165.57% |
| 2025-03-31 | -676.56% |
| 2024-12-31 | -347.41% |
| 2024-09-30 | -270.62% |
| 2024-06-30 | -254.47% |
| 2024-03-31 | -159.14% |
| 2023-12-31 | -163.47% |
| 2023-09-30 | -103.50% |
| 2023-06-30 | -121.84% |
| 2023-03-31 | -84.97% |
| 2022-12-31 | -73.84% |
| 2022-09-30 | -95.70% |
